Ipilimumab, for use in advanced melanoma, was the first approved ICI in 2011, and is a drug that targets the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint. The gene discussed is CTLA4; the disease is melanoma.